Two recent studies from researchers at Washington University School of Medicine in St. Louis have identified a promising way ...

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

There are now several classes of FLT3 inhibitors in development with varying ... time tumor sampling for pharmacodynamic monitoring of drug activity with minimal patient discomfort or risk.

FLT3 mutation is a highly relevant target given its specificity and role in the biology of AML. There are a number of small-molecule receptor tyrosine kinase inhibitors that target FLT3 ...

This type of AML can be treated with established drugs called FLT3 inhibitors, but the cancer often develops resistance to this treatment over time. Because the RSK1 inhibitor blocks a different ...

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

and issues with drug resistance. To address these challenges medicinal chemists have used a macrocyclization strategy to optimize these molecules and three macrocyclic kinase inhibitors (lorlatinib ...

The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

This type of AML can be treated with established drugs called FLT3 inhibitors, but the cancer often develops resistance to this treatment over time. Because the RSK1 inhibitor blocks a different ...